

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Single Technology Appraisal

Ustekinumab for treating moderately to severely active ulcerative colitis I[D1511]

Matrix of consultees and commentators

Consultees	Commentators (no right to submit or appeal)
<p><u>Company</u></p> <ul style="list-style-type: none"> • Janssen-Cilag (ustekinumab) <p><u>Patient/carer groups</u></p> <ul style="list-style-type: none"> • Bladder and Bowel Community • Bowel Cancer UK • Colostomy UK • Crohn's and Colitis UK • Muslim Council of Britain • South Asian Health Foundation • Specialised Healthcare Alliance • Ulcerative Colitis UK <p><u>Professional groups</u></p> <ul style="list-style-type: none"> • Association of Anaesthetists of Great Britain and Ireland • Association of Coloproctology of Great Britain and Ireland • Association of Surgeons of Great Britain and Ireland • British Geriatrics Society • British Society of Gastroenterology • Primary Care Society for Gastroenterology • Royal College of Anaesthetists • Royal College of General Practitioners • Royal College of Nursing • Royal College of Pathologists • Royal College of Physicians • Royal College of Surgeons • Royal Pharmaceutical Society • Royal Society of Medicine • UK Clinical Pharmacy Association <p><u>Others</u></p> <ul style="list-style-type: none"> • Department of Health and Social Care 	<p><u>General</u></p> <ul style="list-style-type: none"> • All Wales Therapeutics and Toxicology Centre • Allied Health Professionals Federation • Board of Community Health Councils in Wales • British National Formulary • Care Quality Commission • Department of Health, Social Services and Public Safety for Northern Ireland • Healthcare Improvement Scotland • Medicines and Healthcare products Regulatory Agency • National Association of Primary Care • National Pharmacy Association • NHS Alliance • NHS Confederation • Scottish Medicines Consortium • Scottish Society of Gastroenterology • Welsh Health Specialised Services Committee <p><u>Possible comparator companies</u></p> <ul style="list-style-type: none"> • AbbVie (adalimumab) • Amgen Europe (adalimumab) • Biogen Idec (infliximab) • Boehringer Ingelheim International (adalimumab) • Celltrion Healthcare (infliximab) • Merck Sharp & Dohme (infliximab, golimumab) • Napp Pharmaceuticals (infliximab) • Pfizer (infliximab, tofacitinib) • Samsung Bioepis UK (adalimumab, infliximab) • Sandoz (adalimumab, infliximab)

Matrix for the technology appraisal of ustekinumab for treating moderately to severely active ulcerative colitis ID1511.

Issue date: April 2019

© National Institute for Health and Care Excellence 2019. All rights reserved.

Page 1 of 3

Consultees	Commentators (no right to submit or appeal)
<ul style="list-style-type: none"> • NHS England • NHS North Derbyshire CCG • NHS Thurrock CCG • Welsh Government 	<ul style="list-style-type: none"> • Takeda UK (vedolizumab) <p><u>Relevant research groups</u></p> <ul style="list-style-type: none"> • Cochrane Inflammatory Bowel Disease and Functional Bowel Disorders Group • Guts UK • Genomics England • Health Research Authority • MRC Clinical Trials Unit • National Institute for Health Research <p><u>Associated Public Health groups</u></p> <ul style="list-style-type: none"> • Public Health England • Public Health Wales

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the lists in the matrix, and which organisations we should include that have a particular focus on relevant equality issues.

PTO FOR DEFINITIONS OF CONSULTEES AND COMMENTATORS

Consultees

Organisations that accept an invitation to participate in the appraisal; the company that markets the technology; national professional organisations; national patient organisations; the Department of Health and Social Care and the Welsh Government and relevant NHS organisations in England.

The company that markets the technology is invited to make an evidence submission, respond to consultations, nominate clinical specialists and has the right to appeal against the Final Appraisal Document (FAD).

All non-company consultees are invited to submit a statement¹, respond to consultations, nominate clinical specialists or patient experts and have the right to appeal against the Final Appraisal Document (FAD).

Commentators

Organisations that engage in the appraisal process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FAD for information only, without right of appeal. These organisations are: companies that market comparator technologies; Healthcare Improvement Scotland; other related research groups where appropriate (for example, the Medical Research Council [MRC], National Cancer Research Institute); other groups (for example, the NHS Confederation, NHS Alliance, and the British National Formulary).

All non-company commentators are invited to nominate clinical specialists or patient experts.

¹ Non-company consultees are invited to submit statements relevant to the group they are representing.